Matthew K. Szot - 29 Dec 2025 Form 4 Insider Report for Cadrenal Therapeutics, Inc. (CVKD)

Reporting relationship: Chief Financial Officer
Issuer ticker: CVKD
Reported as of: 29 Dec 2025
Net transaction value: -$69,233
SEC form: 4
Accepted by SEC: 31 Dec 2025, 16:05:19 UTC
Prior SEC filing: 05 Dec 2025
Next SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew K. Szot

Key filing fact

Matthew K. Szot filed Form 4 for Cadrenal Therapeutics, Inc. (CVKD) on 31 Dec 2025.

Key facts

This page summarizes Matthew K. Szot's Form 4 filing for Cadrenal Therapeutics, Inc. (CVKD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 31 Dec 2025, 16:05.

Change

Previous filing in this sequence was filed on 05 Dec 2025.
Current net transaction value: -$69,233.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001401385 Primary reporting owner

Szot Matthew K

Relationship: Chief Financial Officer
Address: C/O CADRENAL THERAPEUTICS, INC.,, 822, A1A NORTH, SUITE 306, PONTE VEDRA,
Signature: /s/ Matthew K. Szot
Signature date: 31 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CVKD transaction

Common Stock

Sale

Transaction value: $69,233
Shares: -9,933
Change %: -100%
Price: $6.97
Shares after: 0
Date: 29 Dec 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 18, 2025, in multiple transactions at prices ranging from $6.83 through $7.37, inclusive, having a weighted average price as shown in column 4 of $6.97. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.